How have OGEN shares performed in 2023?

Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,192.1% and is now trading at $3.46. View the best growth stocks for 2023 here .

Are investors shorting Oragenics?

Oragenics saw a decrease in short interest in October. As of October 31st, there was short interest totaling 52,400 shares, a decrease of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.5% of the shares of the company are short sold. View Oragenics' Short Interest .

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.85) EPS for the quarter. The biotechnology company earned $0.01 million during the quarter.

When did Oragenics' stock split?

Oragenics shares reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN) , Jaguar Health (JAGX) , Biocept (BIOC) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Heat Biologics (HTBX) , Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV) .

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Oragenics Stock Price, News & Analysis (NYSEAMERICAN:OGEN)

$3.46

-0.12 (-3.35%)

(As of 12/1/2023 ET)

Compare

Today's Range: $3.46
▼
$3.80
50-Day Range: $2.94
▼
$4.18
52-Week Range: $2.60
▼
$12.33

Volume: 7,923 shs
Average Volume: 3,952 shs
Market Capitalization: $8.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest

Oragenics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: Selling Shares
$12,495 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Oragenics.

5.0

Short Interest

Percentage of Shares Shorted
2.11% of the float of Oragenics has been sold short.
Short Interest Ratio / Days to Cover
Oragenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oragenics has recently decreased by 12.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Oragenics does not currently pay a dividend.
Dividend Growth
Oragenics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OGEN.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Oragenics this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for OGEN on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Oragenics to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oragenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,495.00 in company stock.
Percentage Held by Insiders
24.60% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.07% of the stock of Oragenics is held by institutions.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Oragenics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oragenics Stock (NYSEAMERICAN:OGEN)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OGEN Stock News Headlines

December 2, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Oragenics (NYSEAMERICAN:OGEN)

November 26, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Oragenics (NYSEAMERICAN:OGEN)

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 6, 2023 | finance.yahoo.com

Oragenics, Inc. (UAV.F)

November 2, 2023 | finance.yahoo.com

Oragenics Issues Update to Shareholders

October 5, 2023 | marketwatch.com

Oragenics Shares Rise 15% After Deal to Buy Some Odyssey Health Assets

October 5, 2023 | finance.yahoo.com

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

October 2, 2023 | msn.com

Oragenics, AVITA Medical among healthcare movers

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 29, 2023 | marketwatch.com

Stocks to Watch: Oragenics, Natuzzi, Syndax Pharmaceuticals

September 29, 2023 | finance.yahoo.com

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

August 7, 2023 | finance.yahoo.com

Oragenics, Inc. Announces Private Placement

June 5, 2023 | finance.yahoo.com

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

March 29, 2023 | finance.yahoo.com

Oragenics to Participate in the World Vaccine Congress Washington

March 14, 2023 | finance.yahoo.com

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

March 8, 2023 | finance.yahoo.com

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

March 1, 2023 | finance.yahoo.com

Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact

March 1, 2023 | finance.yahoo.com

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

February 3, 2023 | financialpost.com

Oragenics, Inc. Regains Compliance with NYSE American

December 23, 2022 | finance.yahoo.com

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

December 22, 2022 | finance.yahoo.com

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

December 20, 2022 | finance.yahoo.com

Oragenics, Inc. Receives NYSE American Notice

December 19, 2022 | financialpost.com

Oragenics, Inc. Announces New Chair

October 24, 2022 | finance.yahoo.com

Oragenics to Participate in the 2022 BioFlorida Annual Conference

September 30, 2022 | benzinga.com

Oral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - Benzinga

September 9, 2022 | morningstar.com

Oragenics Inc OGEN Stock Quote

September 7, 2022 | reuters.com

OGEN.P - Oragenics Inc | Stock Price & Latest News | Reuters

See More Headlines

Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:OGEN
CUSIP: N/A
CIK: 1174940
Web: www.oragenics.com
Phone: 813-286-7900
Fax: 813-286-7904
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,290,000.00
Net Margins: N/A
Pretax Margin: -26,700.00%
Return on Equity: -132.48%
Return on Assets: -93.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.57
Quick Ratio: 5.57

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 68.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.91 per share
Price / Book: 1.81

Miscellaneous

Outstanding Shares: 2,570,000
Free Float: 1,937,000
Market Cap: $8.89 million
Optionable: Not Optionable
Beta: 0.53

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Ms. Kimberly M. Murphy (Age 60)
President, CEO & Director
Comp: $497.03k
Ms. Janet Huffman (Age 51)
CFO, Secretary & Treasurer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed in 2023?: Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,192.1% and is now trading at $3.46.
View the best growth stocks for 2023 here.
Are investors shorting Oragenics?: Oragenics saw a decrease in short interest in October. As of October 31st, there was short interest totaling 52,400 shares, a decrease of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.5% of the shares of the company are short sold.
View Oragenics' Short Interest.
How were Oragenics' earnings last quarter?: Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.85) EPS for the quarter. The biotechnology company earned $0.01 million during the quarter.
When did Oragenics' stock split?: Oragenics shares reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).
How do I buy shares of Oragenics?: Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:OGEN) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oragenics Stock Price, News & Analysis (NYSEAMERICAN:OGEN)

Oragenics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score